Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

29/09/2016 ​Barcelona, a Friendly Ecosystem for Start-Ups 22/09/2016 Barcelona, capital of particle accelerators science and technology 15/09/2016 Tech Companies With More Than $1 Million Raised: Barcelona Ranks 5th In Europe 09/09/2016 ​UB and UAB Universities Stand out in Spain According to Main International Rankings 31/08/2016 New CaixaBank's Data Center Implementation Completed In Barcelona Synchrotron Park 25/08/2016 ​Barcelona, 4th most creative city in the world
22 23 24 25 26 27 28 29 30 31 32